Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Sophiris Bio Inc. (SPHS)

0.0349   0.006 (20.76%) 03-03 16:11
Open: 0.0364 Pre. Close: 0.0289
High: 0.0364 Low: 0.027
Volume: 196,905 Market Cap: 1M
Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.04 - 0.04 0.04 - 0.04
Low: 0.03 - 0.03 0.03 - 0.03
Close: 0.03 - 0.03 0.03 - 0.03

Technical analysis

as of: 2021-03-03 3:33:23 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 0.05     One year: 0.07
Support: Support1: 0.02    Support2: 0.02
Resistance: Resistance1: 0.04    Resistance2: 0.06
Pivot: 0.04
Moving Average: MA(5): 0.03     MA(20): 0.04
MA(100): 0.02     MA(250): 0.06
MACD: MACD(12,26):     Signal(9):
Stochastic oscillator: %K(14,3): 39.33     %D(3): 31.63
RSI: RSI(14): 51.28
52-week: High: 0.72  Low: 0.01  Change(%): -94.9
Average Vol(K): 3-Month: 50470  10-Days: 27865

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
SPHS has closed above bottom band by 45.3%. Bollinger Bands are 27.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 21 Oct 2020
SPHS Stock Forecast, Price & News (Sophiris Bio) - MarketBeat

Thu, 15 Oct 2020
Pipeline Therapeutics Appoints Peter Slover as Chief Financial Officer - Business Wire

Mon, 18 May 2020
Sophiris Bio To Shut Down Operations - Yahoo Finance

Tue, 10 Mar 2020
Sophiris Bio Announces Nasdaq Delisting Nasdaq:SPHS - GlobeNewswire

Mon, 18 Nov 2019
SPHS: Single Phase 3 Clinical Trial Planned for Topsalysin in Localized Prostate Cancer… - Yahoo Finance

Mon, 21 Oct 2019
Sophiris Bio Receives Positive Feedback from FDA Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design - PRNewswire

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Underperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Outperform Debt to Equity: Underperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 34
Shares Float (M) 33
% Held by Insiders
% Held by Institutions 5.42
Shares Short (K) 1,370
Shares Short P. Month (K) 1,510

Stock Financials

EPS 0.001
EPS Est This Year -0.320
EPS Est Next Year -0.500
Book Value (p.s.) -0.080
Profit Margin
Operating Margin
Return on Assets (ttm) -56.4
Return on Equity (ttm)
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -0.292
Qtrly Earnings Growth
Operating Cash Flow (M) -11
Levered Free Cash Flow (M) -7

Stock Valuations

PE Ratio 35.40
PEG Ratio
Price to Book value -0.44
Price to Sales
Price to Cash Flow -0.12

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.